A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease
Sponsor: |
Teva Pharmaceuticals |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAO2317 |
U.S. Govt. ID: |
NCT02215616 |
Contact: |
Ronda Clouse: 212-305-2387 / rc2682@columbia.edu |
This study is for patients with Huntington's Disease (HD). The purpose of this clinical study is to find out whether a drug called laquinimod at different doses is safe, and whether it is helpful for people with Huntingtons disease (HD). Laquinimod, the drug being studied in this project, has not been studied in patients with Huntingtons disease. Studies have been conducted using this drug for patients with Multiple Sclerosis, Systemic lupus erythematosus (SLE) and Crohns disease. This study is being conducted to determine if laquinimod helps with the signs and symptoms of Huntingtons disease.
This study is closed
Investigator
Karen Marder, MD, MPH
Do you have a clinical diagnosis of Huntington's Disease? |
Yes |
No |